[1] Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines 2019;4:39. https://doi.org/10.1038/s41541-019-0132-6.
[2] Renoud L, Khouri C, Revol B, Lepelley M, Perez J, Roustit M, et al. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Intern Med 2021;181:1243–5. https://doi.org/10.1001/jamainternmed.2021.2219.
[3] Shemer A, Pras E, Einan-Lifshitz A, Dubinsky-Pertzov B, Hecht I. Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study. JAMA Otolaryngol Head Neck Surg 2021;147:739–43. https://doi.org/10.1001/jamaoto.2021.1259.
[4] Galeotti F, Massari M, D’Alessandro R, Beghi E, Chiò A, Logroscino G, et al. Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination. Eur J Epidemiol 2013;28:433–44. https://doi.org/10.1007/s10654-013-9797-8.
[5] Khan Z, Ahmad U, Ualiyeva D, Amissah OB, Khan A, Noor Z, et al. Guillain-Barre syndrome: An autoimmune disorder post-COVID-19 vaccination? Clin Immunol Communications 2022;2:1–5. https://doi.org/10.1016/j.clicom.2021.12.002.
[6] Dalwadi V, Hancock D, Ballout AA, Geraci A. Axonal-Variant Guillian-Barre Syndrome Temporally Associated With mRNA-Based Moderna SARS-CoV-2 Vaccine. Cureus 2021;13:e18291. https://doi.org/10.7759/cureus.18291.
[7] Bijoy George T, Kainat A, Pachika PS, Arnold J. Rare occurrence of Guillain-Barré syndrome after Moderna vaccine. BMJ Case Rep 2022;15:e249749. https://doi.org/10.1136/bcr-2022-249749.
[8] Matarneh AS, Al-battah AH, Farooqui K, Ghamoodi M, Alhatou M. COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. Clin Case Rep 2021;9:e04756. https://doi.org/10.1002/ccr3.4756.
[9] Masuccio FG, Comi C, Solaro C. Guillain–Barrè syndrome following COVID-19 vaccine mRNA-1273: a case report. Acta Neurologica Belgica 2021. https://doi.org/10.1007/s13760-021-01838-4.
[10] Sriwastava S, Shrestha AK, Khalid SH, Colantonio MA, Nwafor D, Srivastava S. Spectrum of Neuroimaging Findings in Post-COVID-19 Vaccination: A Case Series and Review of Literature. Neurol Int 2021;13. https://doi.org/10.3390/neurolint13040061.
[11] Hughes DL, Brunn JA, Jacobs J, Todd PK, Askari FK, Fontana RJ. Guillain-Barré Syndrome After COVID-19 mRNA Vaccination in a Liver Transplantation Recipient With Favorable Treatment Response. Liver Transpl 2022;28:134–7. https://doi.org/10.1002/lt.26279.
[12] Aomar-Millán IF, Martínez de Victoria-Carazo J, Peregrina-Rivas JA, Villegas-Rodríguez I. COVID-19, Guillain-Barré syndrome, and the vaccine. A dangerous combination. Rev Clín Esp (Engl Ed) 2021;221:555–7. https://doi.org/10.1016/j.rceng.2021.05.002.
[13] Bouattour N, Hdiji O, Sakka S, Fakhfakh E, Moalla K, Daoud S, et al. Guillain-Barré syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases. Neurol Sci 2022;43:755–61. https://doi.org/10.1007/s10072-021-05733-x.
[14] Fukushima T, Tomita M, Ikeda S, Hattori N. A case of sensory ataxic Guillain–Barré syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer). QJM 2022;115:25–7. https://doi.org/10.1093/qjmed/hcab296.
[15] Kim JW, Kim YG, Park YC, Choi S, Lee S, Min HJ, et al. Guillain-Barre Syndrome After Two COVID-19 Vaccinations: Two Case Reports With Follow-up Electrodiagnostic Study. J Korean Med Sci 2022;37. https://doi.org/10.3346/jkms.2022.37.e58.
[16] Kim Y, Zhu Z, Kochar P, Gavigan P, Kaur D, Kumar A. A Pediatric Case of Sensory Predominant Guillain-Barré Syndrome Following COVID-19 Vaccination. Child Neurol Open 2022;9:2329048X221074549. https://doi.org/10.1177/2329048X221074549.
[17] Yamada S, Yamada K, Nishida H. A Case of Sequential Development of Polymyalgia Rheumatica and Guillain-Barré Syndrome Following Administration of the Pfizer-BioNTech COVID-19 Vaccine. Intern Med 2022;advpub. https://doi.org/10.2169/internalmedicine.0319-22.
[18] Trimboli M, Zoleo P, Arabia G, Gambardella A. Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine. Neurol Sci 2021;42:4401–2. https://doi.org/10.1007/s10072-021-05523-5.
[19] Malamud E, Otallah SI, Caress JB, Lapid DJ. Guillain-Barré Syndrome After COVID-19 Vaccination in an Adolescent. Pediatr Neurol 2022;126:9–10. https://doi.org/10.1016/j.pediatrneurol.2021.10.003.
[20] Ogbebor O, Seth H, Min Z, Bhanot N. Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association. IDCases 2021;24:e01143. https://doi.org/10.1016/j.idcr.2021.e01143.
[21] Min YG, Ju W, Ha Y-E, Ban J-J, Lee SA, Sung J-J, et al. Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature. J Neuroimmunol 2021;359. https://doi.org/10.1016/j.jneuroim.2021.577691.
[22] Biswas A, Pandey SK, Kumar D, Vardhan H. Post Coronavirus Disease‑2019 Vaccination Guillain‑Barré Syndrome. Indian J Public Health 2021;65:422–4. https://doi.org/10.4103/ijph.ijph_1716_21.
[23] Aldeeb M, Okar L, Mahmud SS, Adeli GA. Could Guillain–Barré syndrome be triggered by COVID-19 vaccination? Clin Case Rep 2022;10:e05237. https://doi.org/10.1002/ccr3.5237.
[24] Kanabar G, Wilkinson P. Guillain‐Barré syndrome presenting with facial diplegia following COVID‐19 vaccination in two patients. BMJ Case Rep 2021;14:e244527. https://doi.org/10.1136/bcr-2021-244527.
[25] Introna A, Caputo F, Santoro C, Guerra T, Ucci M, Mezzapesa DM, et al. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association? Clin Neurol Neurosurg 2021;208:106887. https://doi.org/10.1016/j.clineuro.2021.106887.
[26] McKean N, Chircop C. Guillain-Barré syndrome after COVID-19 vaccination. BMJ Case Rep 2021;14:e244125. https://doi.org/10.1136/bcr-2021-244125.
[27] Kripalani Y, Lakkappan V, Parulekar L, Shaikh A, Singh R, Vyas P. A Rare Case of Guillain-Barré Syndrome following COVID-19 Vaccination. EJCRIM 2021;8. https://doi.org/10.12890/2021_002797.
[28] Hasan T, Khan M, Khan F, Hamza G. Case of Guillain-Barré syndrome following COVID-19 vaccine. BMJ Case Rep 2021;14:e243629. https://doi.org/10.1136/bcr-2021-243629.
[29] James J, Jose J, Gafoor VA, Smita B, Balaram N. Guillain-Barré syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination: A case series. Neurol Clin Neurosci 2021;9:402–5. https://doi.org/10.1111/ncn3.12537.
[30] da Silva GF, da Silva CF, Oliveira REN da N, Romancini F, Mendes RM, Locks A, et al. Guillain–Barré syndrome after coronavirus disease 2019 vaccine: A temporal association. Clin Exp Neuroimmunol 2022;13:92–4. https://doi.org/10.1111/cen3.12678.
[31] Patel SU, Khurram R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep 2021;14:e242956. https://doi.org/10.1136/bcr-2021-242956.
[32] Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, et al. Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination. Ann Neurol 2021;90:315–8. https://doi.org/10.1002/ana.26144.
[33] Tabatabaee S, Rezania F, Alwedaie SMJ, Malekdar E, Badi Z, Tabatabaei SM, et al. Post COVID-19 vaccination Guillain-Barre syndrome: three cases. Hum Vaccin Immunother 2022;18:2045153. https://doi.org/10.1080/21645515.2022.2045153.
[34] Karimi N, Boostani R, Fatehi F, Panahi A, Okhovat AA, Ziaadini B, et al. Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients. BCN 2021;12:703–10. https://doi.org/10.32598/bcn.2021.3565.1.
[35] Thant HL, Morgan R, Paese MM, Persaud T, Diaz J, Hurtado L. Guillain-Barré Syndrome After Ad26.COV2.S Vaccination. Am J Case Rep 2022;23:e935275-1-e935275-5. https://doi.org/10.12659/AJCR.935275.
[36] Zubair AS, Bae JY, Desai K. Facial Diplegia Variant of Guillain-Barré Syndrome in Pregnancy Following COVID-19 Vaccination: A Case Report. Cureus 2022;14:e22341. https://doi.org/10.7759/cureus.22341.
[37] Rossetti A, Gheihman G, O’Hare M, Kosowsky JM. Guillain-Barré Syndrome Presenting as Facial Diplegia after COVID-19 Vaccination: A Case Report. J Emerg Med 2021;61:e141–5. https://doi.org/10.1016/j.jemermed.2021.07.062.
[38] Prasad A, Hurlburt G, Podury S, Tandon M, Kingree S, Sriwastava S. A Novel Case of Bifacial Diplegia Variant of Guillain-Barré Syndrome Following Janssen COVID-19 Vaccination. Neurol Int 2021;13. https://doi.org/10.3390/neurolint13030040.
[39] Stefanou MI, Karachaliou E, Chondrogianni M, Moschovos C, Bakola E, Foska A, et al. Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy. Neurol Res Pract 2022;4:6. https://doi.org/10.1186/s42466-022-00172-1.
[40] Castiglione JI, Crespo JM, Lecchini L, Silveira FO, Luis MB, Cotti N, et al. Bilateral facial palsy with paresthesias, variant of Guillain-Barré syndrome following COVID-19 vaccine: A case series of 9 patients. Neuromuscul Disord 2022;32:572–4. https://doi.org/10.1016/j.nmd.2022.05.003.
[41] Lunn MP, Cornblath DR, Jacobs BC, Querol L, van Doorn PA, Hughes RA, et al. COVID-19 vaccine and Guillain-Barré syndrome: let’s not leap to associations. Brain 2021;144:357–60. https://doi.org/10.1093/brain/awaa444.
[42] García-Grimshaw M, Michel-Chávez A, Vera-Zertuche JM, Galnares-Olalde JA, Hernández-Vanegas LE, Figueroa-Cucurachi M, et al. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clin Immunol 2021;230:108818. https://doi.org/10.1016/j.clim.2021.108818.
[43] Hanson KE, Goddard K, Lewis N, Fireman B, Myers TR, Bakshi N, et al. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Netw Open 2022;5:e228879–e228879. https://doi.org/10.1001/jamanetworkopen.2022.8879.
[44] Osowicki J, Morgan H, Harris A, Crawford NW, Buttery JP, Kiers L. Guillain-Barré Syndrome in an Australian State Using Both mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines. Ann Neurol 2021;90:856–8. https://doi.org/10.1002/ana.26218.
[45] Keh RYS, Scanlon S, Datta-Nemdharry P, Donegan K, Cavanagh S, Foster M, et al. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database. Brain 2022:awac067. https://doi.org/10.1093/brain/awac067.
[46] Dyer O. Covid-19: Regulators warn that rare Guillain-Barré cases may link to J&J and AstraZeneca vaccines. BMJ 2021;374:n1786. https://doi.org/10.1136/bmj.n1786.
[47] Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, et al. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience. Muscle Nerve 2020;62:485–91. https://doi.org/10.1002/mus.27024.
[48] Po ALW. Non-parenteral vaccines. BMJ 2004;329:62. https://doi.org/10.1136/bmj.329.7457.62.
[49] Wan EYF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan VKC, et al. Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis 2022;22:64–72. https://doi.org/10.1016/S1473-3099(21)00451-5.
[50] Poudel S, Nepali P, Baniya S, Shah S, Bogati S, Nepal G, et al. Bell’s palsy as a possible complication of mRNA-1273 (Moderna) vaccine against COVID-19. Ann Med Surg 2022;78:103897. https://doi.org/10.1016/j.amsu.2022.103897.
[51] Cellina M, D’Arrigo A, Floridi C, Oliva G, Carrafiello G. Left Bell’s palsy following the first dose of mRNA-1273 SARS-CoV-2 vaccine: A case report. Clinical Imaging 2022;82:1–4. https://doi.org/10.1016/j.clinimag.2021.10.010.
[52] Martin-Villares C, Vazquez-Feito A, Gonzalez-Gimeno MJ, de la Nogal-Fernandez B. Bell’s palsy following a single dose of mRNA SARS-CoV-2 vaccine: a case report. J Neurol 2022;269:47–8. https://doi.org/10.1007/s00415-021-10617-3.
[53] Iftikhar H, Noor SMU, Masod M, Bashir K. Bell’s Palsy After 24 Hours of mRNA-1273 SARS CoV- 2 Vaccine. Cureus 2021;13:e15935. https://doi.org/10.7759/cureus.15935.
[54] Pothiawala S. Bell’s Palsy After Second Dose of Moderna COVID-19 Vaccine: Coincidence or Causation? AML 2021;28. https://doi.org/10.15388/Amed.2021.28.2.7.
[55] Burrows A, Bartholomew T, Rudd J, Walker D. Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses. BMJ Case Rep 2021;14:e243829. https://doi.org/10.1136/bcr-2021-243829.
[56] Obermann M, Krasniqi M, Ewers N, Fayad J, Haeberle U. Bell’s palsy following COVID-19 vaccination with high CSF antibody response. Neurol Sci 2021;42:4397–9. https://doi.org/10.1007/s10072-021-05496-5.
[57] Mussatto CC, Sokol J, Alapati N. Bell’s palsy following COVID-19 vaccine administration in HIV+ patient. Am J Ophthalmol Case Rep 2022;25:101259. https://doi.org/10.1016/j.ajoc.2022.101259.
[58] Colella G, Orlandi M, Cirillo N. Bell’s palsy following COVID-19 vaccination. J Neurol 2021;268:3589–91. https://doi.org/10.1007/s00415-021-10462-4.
[59] Gómez de Terreros Caro G, Gil Díaz S, Pérez Alé M, Martínez Gimeno ML. Bell’s palsy following COVID-19 vaccination: a case report. Neurología (Engl Ed) 2021;36:567–8. https://doi.org/10.1016/j.nrleng.2021.04.002.
[60] Tahir N, Koorapati G, Prasad S, Jeelani HM, Sherchan R, Shrestha J, et al. SARS-CoV-2 Vaccination-Induced Transverse Myelitis. Cureus 2021;13:e16624. https://doi.org/10.7759/cureus.16624.
[61] Nishizawa Y, Hoshina Y, Baker V. Bell’s palsy following the Ad26.COV2.S COVID-19 vaccination. QJM 2021;114:657–8. https://doi.org/10.1093/qjmed/hcab143.
[62] Burrows A, Bartholomew T, Rudd J, Walker D. Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses. BMJ Case Reports 2021;14:e243829. https://doi.org/10.1136/bcr-2021-243829.
[63] Tamaki A, Cabrera CI, Li S, Rabbani C, Thuener JE, Rezaee RP, et al. Incidence of Bell Palsy in Patients With COVID-19. JAMA Otolaryngology–Head & Neck Surgery 2021;147:767–8. https://doi.org/10.1001/jamaoto.2021.1266.
[64] McCormick DavidP. Herpes-Simplex virus as cause of Bell’s palsy. Lancet 1972;299:937–9. https://doi.org/10.1016/S0140-6736(72)91499-7.
[65] Tseng H-F, Sy LS, Ackerson BK, Hechter RC, Tartof SY, Haag M, et al. Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds. Pediatrics 2017;139:e20162084. https://doi.org/10.1542/peds.2016-2084.
[66] Shibli R, Barnett O, Abu-Full Z, Gronich N, Najjar-Debbiny R, Doweck I, et al. Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell’s palsy: a population-based study. Lancet Reg Health Eur 2021;11:100236. https://doi.org/10.1016/j.lanepe.2021.100236.
[67] Wan EYF, Chui CSL, Ng VWS, Wang Y, Yan VKC, Lam ICH, et al. Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination With BNT162b2 Increased Risk of Bell’s Palsy: A Nested Case-Control and Self-Controlled Case Series Study. Clin Infect Dis 2022:ciac460. https://doi.org/10.1093/cid/ciac460.
[68] Frontera JA, Tamborska AA, Doheim MF, Garcia-Azorin D, Gezegen H, Guekht A, et al. Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System. Ann Neurol 2022;91:756–71. https://doi.org/10.1002/ana.26339.
[69] Chamberlin T. C. The Method of Multiple Working Hypotheses. Science 1890;ns-15:92–6. https://doi.org/10.1126/science.ns-15.366.92.
[70] VAERS. Vaccine Adverse Event Reporting System. U.S. Department of Health & Human Services; 2021.
[71] Ricke DO. Vaccines Associated Cardiac Adverse Events, including SARS-CoV-2 Myocarditis, Elevated Histamine Etiology Hypothesis. J Virol Viral Dis 2022;2. https://doi.org/10.54289/JVVD2200108.
[72] Clark AK, Old EA, Malcangio M. Neuropathic pain and cytokines: current perspectives. J Pain Res 2013;6:803–14. https://doi.org/10.2147/JPR.S53660.
[73] Zhang J-M, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin 2007;45:27–37. https://doi.org/10.1097/AIA.0b013e318034194e.
[74] Thacker MA, Clark AK, Marchand F, McMahon SB. Pathophysiology of Peripheral Neuropathic Pain: Immune Cells and Molecules. Anesth Analg 2007;105. https://doi.org/10.1213/01.ane.0000275190.42912.37.
[75] Yu J, Lou G-D, Yue J-X, Tang Y-Y, Hou W-W, Shou W-T, et al. Effects of histamine on spontaneous neuropathic pain induced by peripheral axotomy. Neurosci Bull 2013;29:261–9. https://doi.org/10.1007/s12264-013-1316-0.
[76] Babazadeh A, Mohseni Afshar Z, Javanian M, Mohammadnia-Afrouzi M, Karkhah A, Masrour-Roudsari J, et al. Influenza Vaccination and Guillain-Barré Syndrome: Reality or Fear. J Transl Int Med 2019;7:137–42. https://doi.org/10.2478/jtim-2019-0028.
[77] Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011;29:599–612. https://doi.org/10.1016/j.vaccine.2010.06.003.
[78] Agrawal S, Verma K, Verma I, Gandhi J. Reactivation of Herpes Zoster Virus After COVID-19 Vaccination: Is There Any Association? Cureus 2022;14:e25195. https://doi.org/10.7759/cureus.25195.
[79] Plüß M, Mese K, Kowallick JT, Schuster A, Tampe D, Tampe B. Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2. Front Immunol 2022;12. https://doi.org/10.3389/fimmu.2021.784145.
[80] Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011;31:986–1000. https://doi.org/10.1161/ATVBAHA.110.207449.
[81] Kawabata A. Prostaglandin E2 and Pain—An Update. Biol Pharm Bull 2011;34:1170–3. https://doi.org/10.1248/bpb.34.1170.
[82] Soeiro T, Salvo F, Pariente A, Grandvuillemin A, Jonville-Béra A-P, Micallef J. Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell’s palsy. Therapie 2021;76:365–7. https://doi.org/10.1016/j.therap.2021.03.005.
[83] Fernandez PEL, Pereira JM, Risso IF, Rodrigues Silva PB, Freitas Barboza ICF, Silveira CGV, et al. Guillain-Barre syndrome following COVID-19 vaccines: A scoping review. Acta Neurol Scand 2022;145:393–8. https://doi.org/10.1111/ane.13575.
[84] Goud R, Lufkin B, Duffy J, Whitaker B, Wong H-L, Liao J, et al. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries. JAMA Intern Medi 2021;181:1623–30. https://doi.org/10.1001/jamainternmed.2021.6227.
[85] Scendoni R, Petrelli C, Scaloni G, Logullo FO. Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine. Hum Vaccin Immunother 2021;17:4093–6. https://doi.org/10.1080/21645515.2021.1954826.
[86] Hanson KE, Goddard K, Lewis N, Fireman B, Myers TR, Bakshi N, et al. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Network Open 2022;5:e228879–e228879. https://doi.org/10.1001/jamanetworkopen.2022.8879.
[87] Röltgen K, Nielsen SCA, Silva O, Younes SF, Zaslavsky M, Costales C, et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 2022;185:1025-1040.e14. https://doi.org/10.1016/j.cell.2022.01.018.
[88] Galdiero MR, Varricchi G, Seaf M, Marone G, Levi-Schaffer F, Marone G. Bidirectional Mast Cell–Eosinophil Interactions in Inflammatory Disorders and Cancer. Front Med 2017;4.
[89] Rosa AC, Fantozzi R. The role of histamine in neurogenic inflammation. Br J Pharmacol 2013;170:38–45. https://doi.org/10.1111/bph.12266.
[90] Dale HH, Laidlaw PP. The physiological action of beta-iminazolylethylamine. J Physiol 1910;41:318–44. https://doi.org/10.1113/jphysiol.1910.sp001406.
[91] Ricke DO. Etiology Model for Elevated Histamine Levels Driving High Reactogenicity Vaccines (including COVID-19) Associated Menstrual Adverse Events. J Infect Dis Ther 2022:1–5. https://doi.org/10.4172/2332-0877.22.S3.002.
[92] Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang X-P, White KM, et al. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Front Pharmacol 2021;12:216. https://doi.org/10.3389/fphar.2021.633680.
[93] Tomera KM, Malone, Robert W., Kittah JK. Brief Report: Rapid Clinical Recovery from Severe COVID-19 with High Dose Famotidine and High Dose Celecoxib Adjuvant Therapy. Enliven: Pharmacovigilance and Drug Safety 2020;6:1–5.
[94] Mather JF, Seip RL, McKay RG. Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19. Am J Gastroenterol 2020;115:1617–23. https://doi.org/10.14309/ajg.0000000000000832.
[95] Sethia R, Prasad M, Mahapatra SJ, Nischal N, Soneja M, Garg P, et al. Efficacy of Famotidine for COVID-19: A Systematic Review and Meta-analysis. MedRxiv 2020:2020.09.28.20203463. https://doi.org/10.1101/2020.09.28.20203463.
[96] Morán Blanco JI, Alvarenga Bonilla JA, Homma S, Suzuki K, Fremont-Smith P, Villar Gómez de Las Heras K. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients. Pulm Pharmacol Ther 2021;67:101989–101989. https://doi.org/10.1016/j.pupt.2021.101989.
[97] Hogan II RB, Hogan III RB, Cannon T, Rappai M, Studdard J, Paul D, et al. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther 2020;63:101942. https://doi.org/10.1016/j.pupt.2020.101942.
[98] Otani IM, Anilkumar AA, Newbury RO, Bhagat M, Beppu LY, Dohil R, et al. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol 2013;131:1576–82. https://doi.org/10.1016/j.jaci.2013.02.042.